Results 191 to 200 of about 2,195,321 (395)

Neuropeptide Ecdysis‐Triggering Hormone and Its Receptor Mediate the Fecundity Improvement of ‘Candidatus Liberibacter Asiaticus’‐Infected Diaphorina citri Females and CLas Proliferation

open access: yesAdvanced Science, EarlyView.
In CLas‐infected D. citri, CLas lowers 20E levels initially, relieving the suppression of ETH release. The subsequent increase in ETH levels upregulates its receptor DcETHR and activates the JH signaling pathway. The signaling cascade of 20E‐ETH/ETHR‐JH along with miR‐210, targeting DcETHR, boost female fecundity in CLas+ D.
Xiaoge Nian   +8 more
wiley   +1 more source

Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis

open access: yes, 2023
American Journal of Hematology, Volume 98, Issue 1, Page E15-E19, January 2023.
Meletios A. Dimopoulos   +16 more
wiley   +1 more source

A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes

open access: yesAmerican Journal of Hematology, Volume 98, Issue 2, Page 272-281, February 2023., 2023
Abstract Patients with relapsed/refractory (R/R) higher‐risk myelodysplastic syndromes (MDS) have a dismal median overall survival (OS) after failing hypomethylating agent (HMA) treatment. There is no standard of care for patients after HMA therapy failure; hence, there is a critical need for effective therapeutic strategies.
Amer M. Zeidan   +18 more
wiley   +1 more source

Applying Ultrasound to Mechanically and Noninvasively Sensitize Prostate Tumors to TRAIL‐Mediated Apoptosis

open access: yesAdvanced Science, EarlyView.
This study explores the application of therapeutic, focal ultrasound to noninvasively enhance the anti‐cancer effects of Tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) as a targeted treatment for prostate cancer. This is achieved by mechanically activating mechanosensitive ion channels within cancer cells.
Abigail R. Fabiano   +10 more
wiley   +1 more source

Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia

open access: yesAmerican Journal of Hematology, Volume 98, Issue 2, Page 338-347, February 2023., 2023
Abstract Bruton tyrosine kinase (BTK) inhibitors have taken a central role in the management of patients with Waldenström macroglobulinemia and are the only agents approved by the Food and Drug Administration (FDA) to treat these patients. Although associated with high rates of durable responses, unmet needs with BTK inhibitor therapy include ...
Jorge J. Castillo   +4 more
wiley   +1 more source

Extravasation of Borrelia burgdorferi Across the Blood–Brain Barrier is an Extremely Rare Event

open access: yesAdvanced Science, EarlyView.
Lyme disease is caused by vascular dissemination of the bacteria Borrelia. In a 3D tissue‐engineered microvessel model, Borrelia extravasation across the blood–brain barrier is extremely rare, implying that neuroborreliosis is not caused via direct cytotoxicity.
Linus Wang   +6 more
wiley   +1 more source

Granular B lymphoblastic leukemia

open access: yes, 2023
American Journal of Hematology, Volume 98, Issue 1, Page 210-211, January 2023.
Biswadip Hazarika, Barbara J. Bain
wiley   +1 more source

Home - About - Disclaimer - Privacy